Get the Stockscreener App
9.20
1.43%
0.13
Elicio Therapeutics Inc stock is traded at $9.20, with a volume of 24,817.
It is up +1.43% in the last 24 hours and up +9.26% over the past month.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
See More
Previous Close:
$9.07
Open:
$9.35
24h Volume:
24,817
Relative Volume:
0.61
Market Cap:
$147.17M
Revenue:
-
Net Income/Loss:
$-33.82M
P/E Ratio:
-0.3595
EPS:
-25.5891
Net Cash Flow:
$-66.04M
1W Performance:
-7.82%
1M Performance:
+9.26%
6M Performance:
+4.43%
1Y Performance:
+96.58%
1-Day Range:
$9.0612
$9.52
1-Week Range:
$8.83
$10.27
52-Week Range:
$3.70
$10.75
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Name
Elicio Therapeutics Inc
Sector
Industry
Phone
(857) 209-0050
Address
451 D STREET, 5TH FLOOR, BOSTON
Compare ELTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
9.20 | 149.89M | 0 | -33.82M | -66.04M | -25.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Elicio Therapeutics Inc Stock (ELTX) Latest News
What recovery options are there for Elicio Therapeutics Inc.Free Market Entry and Exit Point Tips - Newser
Elicio Therapeutics Inc. stock outlook for YEARFree Technical Entry Strategy for Beginners - Newser
Is Elicio Therapeutics Inc. meeting your algorithmic filter criteriaFree Triple Digit Return Stock Predictions - Newser
What does recent volatility data suggest for Elicio Therapeutics Inc.Free Top Gaining Picks With Entry Signals - Newser
Analyzing Elicio Therapeutics Inc. with multi timeframe chartsIntraday Price Forecast Using Volume Models - Newser
Applying chart zones and confluence areas to Elicio Therapeutics Inc.Free AI Based High Gain Watchlist Scanner - Newser
Market reaction to Elicio Therapeutics Inc.’s recent newsFree Daily Momentum Screener With Alerts - Newser
Is Elicio Therapeutics Inc. stock risky to hold nowFlash Gain Trade Picks - mustnews.co.kr
Elicio Therapeutics Inc. Reaches Critical Trendline SupportBuy Signal Based on Chart Analysis Confirmed - metal.it
Using Bollinger Bands to evaluate Elicio Therapeutics Inc.High Yield Watchlist with Filtered Picks - Newser
How hedge fund analytics apply to Elicio Therapeutics Inc. stockFree Sector Based Breakout Stock Forecast - Newser
Elicio (ELTX) Q2 Loss Beats Estimates - AOL.com
What to expect from Elicio Therapeutics Inc. in the next 30 daysEquity Performance Forecast Based on AI Models - Newser
Evaluating Elicio Therapeutics Inc. with trendline analysisFree Daily Stock Market Swing Alerts - Newser
Can trapped investors hope for a rebound in Elicio Therapeutics Inc.AI-Powered Stock Trend Movement Analysis - Newser
Predicting Elicio Therapeutics Inc. trend using moving averagesTechnical Trend Forecast for Investors - Newser
Elicio Therapeutics Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Key External Factors That Drive Elicio Therapeutics Inc. Stock Price MovementsDaily Pick Forecast with Entry Zones - Newser
Elicio Therapeutics (ELTX): Clinical Progress Outpaces Financial Losses - AInvest
Elicio Therapeutics Extends Cash Runway And Advances Cancer Trial - Finimize
Elicio Therapeutics: Q2 Earnings Snapshot - Connecticut Post
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Positive Trial Results: Elicio's Pancreatic Cancer Vaccine Shows Promise, Final Data Coming Q4 2025 - Stock Titan
What makes Elicio Therapeutics Inc. stock price move sharplyValue Investing Checklist with Entry Signals - Newser
Why Elicio Therapeutics Inc. stock attracts strong analyst attentionFree Capital Efficiency Optimized Stock Alerts - Newser
Is Elicio Therapeutics Inc. Stock Overbought or Oversold RSI Indicator AnalysisFree Early Entry Picks Before News Breakout - Newser
How Elicio Therapeutics Inc. stock performs during market volatilitySmart Entry Watchlist with Daily Analysis - Newser
Analyzing recovery setups for Elicio Therapeutics Inc. investorsSmart Forecast Signals from AI Models - Newser
Elicio announces positive recommendation by IDMC to continue ELI-002 Phase 2 - TipRanks
Elicio Therapeutics Advances Phase 2 AMPLIFY-7P Study - TipRanks
Elicio Therapeutics Announces Positive Recommendation by - GlobeNewswire
Breakthrough: Pancreatic Cancer Vaccine ELI-002 Clears Critical Phase 2 Safety Review, Final Results Due Q4 2025 - Stock Titan
Elicio Therapeutics Inc. recovery potential after sell offPrice Action Based Buy Zone Forecast - Newser
Visual trend scoring systems applied to Elicio Therapeutics Inc.Free Safe Entry Stock Watch Suggestions - Newser
Elicio Therapeutics Inc. Recovery Linked to Earnings SurpriseCapital Growth Entry Forecast Insight - beatles.ru
What analysts say about Elicio Therapeutics Inc. stockMarket-beating returns - Jammu Links News
What is the dividend policy of Elicio Therapeutics Inc. stockBuild wealth faster with consistent growth stocks - Jammu Links News
Elicio Therapeutics Inc Stock (ELTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
3.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):